AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC
By Thomson ReutersJun 13, 2025 | 3:40 AM
(Reuters) -AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Tasim Zahid)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.
